牛牛AI助理已提取核心訊息
CRISPR Therapeutics CEO Samarth Kulkarni completed a stock transaction on January 16, 2024, involving the sale of 20,000 shares of common stock. The shares were sold at a price of $62.5029 per share, resulting in a total transaction value of $1,250,058. Prior to this sale, Kulkarni exercised options to acquire the same number of shares at $19.12 each. Following the transactions, Kulkarni's direct holdings in the company amount to 187,377 shares. Additionally, Kulkarni has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT.
CRISPR Therapeutics CEO Samarth Kulkarni completed a stock transaction on January 16, 2024, involving the sale of 20,000 shares of common stock. The shares were sold at a price of $62.5029 per share, resulting in a total transaction value of $1,250,058. Prior to this sale, Kulkarni exercised options to acquire the same number of shares at $19.12 each. Following the transactions, Kulkarni's direct holdings in the company amount to 187,377 shares. Additionally, Kulkarni has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT.
CRISPR Therapeutics首席執行官薩瑪斯·庫爾卡尼於2024年1月16日完成了一項股票交易，涉及出售2萬股普通股。這些股票以每股62.5029美元的價格出售，總交易價值爲1,250,058美元。在此次出售之前，庫爾卡尼行使了期權，以每股19.12美元的價格收購了相同數量的股票。交易完成後，庫爾卡尼在該公司的直接持股量爲187,377股股票。此外，庫爾卡尼通過庫爾卡尼2023年GRAT擁有20萬股股票的間接實益所有權。
CRISPR Therapeutics首席執行官薩瑪斯·庫爾卡尼於2024年1月16日完成了一項股票交易，涉及出售2萬股普通股。這些股票以每股62.5029美元的價格出售，總交易價值爲1,250,058美元。在此次出售之前，庫爾卡尼行使了期權，以每股19.12美元的價格收購了相同數量的股票。交易完成後，庫爾卡尼在該公司的直接持股量爲187,377股股票。此外，庫爾卡尼通過庫爾卡尼2023年GRAT擁有20萬股股票的間接實益所有權。
有用
沒用